HER2-low breast cancer: Trastuzumab-Deruxtecan improves PFS without…

medicine Thursday, June 6, 2024 Chicago Trastuzumab-Deruxtecan delays cancer growth in patients with metastatic, hormone receptor-positive, HER2-low or HER2-ultralow breast cancer that has progressed after endocrine therapy (ET). This is shown by the results of